Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

For CVS, Q2 earnings will be a critical inflection point. A miss could trigger a breakup or further decline, making the stock ...

The coverage change only applies to employer and union insurance plans ... Wegovy will enable more employers to provide coverage for the weight loss category," CVS Health Vice President of External ...

CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.

NEW YORK, July 14 (Reuters) - President Donald Trump's spending bill is set to raise administrative costs and make managing ...

The coverage change applies to CVS Caremark’s most common formulary template, which represents between 25 and 30 million individuals overall.

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Millions of Americans could lose access to healthcare due to new Medicaid requirements in the One Big Beautiful Bill. Here ...

Pharmacy benefit manager CVS Caremark decided to replace Zepbound with Wegovy for use in weight loss starting July 1, despite Zepbound users having more weight loss success.